Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 245

1.

Identification of Immunodominant HIV-1 Epitopes Presented by HLA-C*12:02, a Protective Allele, Using an Immunopeptidomics Approach.

Chikata T, Paes W, Akahoshi T, Partridge T, Murakoshi H, Gatanaga H, Ternette N, Oka S, Borrow P, Takiguchi M.

J Virol. 2019 Aug 13;93(17). pii: e00634-19. doi: 10.1128/JVI.00634-19. Print 2019 Sep 1.

2.

Fibroadipogenic progenitors are responsible for muscle loss in limb girdle muscular dystrophy 2B.

Hogarth MW, Defour A, Lazarski C, Gallardo E, Diaz Manera J, Partridge TA, Nagaraju K, Jaiswal JK.

Nat Commun. 2019 Jun 3;10(1):2430. doi: 10.1038/s41467-019-10438-z.

3.

Application of Magnetic Resonance to Assess Lyophilized Drug Product Reconstitution.

Partridge TA, Ahmed M, Choudhary SB, van der Walle CF, Patel SM, Bishop SM, Mantle MD.

Pharm Res. 2019 Mar 22;36(5):71. doi: 10.1007/s11095-019-2591-x.

4.

Morpholino-induced exon skipping stimulates cell-mediated and humoral responses to dystrophin in mdx mice.

Vila MC, Novak JS, Benny Klimek M, Li N, Morales M, Fritz AG, Edwards K, Boehler JF, Hogarth MW, Kinder TB, Zhang A, Mazala D, Fiorillo AA, Douglas B, Chen YW, van den Anker J, Lu QL, Hathout Y, Hoffman EP, Partridge TA, Nagaraju K.

J Pathol. 2019 Jul;248(3):339-351. doi: 10.1002/path.5263. Epub 2019 Apr 16.

PMID:
30883742
5.

Efficacy of Multi-exon Skipping Treatment in Duchenne Muscular Dystrophy Dog Model Neonates.

Lim KRQ, Echigoya Y, Nagata T, Kuraoka M, Kobayashi M, Aoki Y, Partridge T, Maruyama R, Takeda S, Yokota T.

Mol Ther. 2019 Jan 2;27(1):76-86. doi: 10.1016/j.ymthe.2018.10.011. Epub 2018 Oct 19.

PMID:
30448197
6.

Shorter Phosphorodiamidate Morpholino Splice-Switching Oligonucleotides May Increase Exon-Skipping Efficacy in DMD.

Akpulat U, Wang H, Becker K, Contreras A, Partridge TA, Novak JS, Cirak S.

Mol Ther Nucleic Acids. 2018 Dec 7;13:534-542. doi: 10.1016/j.omtn.2018.10.002. Epub 2018 Oct 10.

7.

Direct solid state NMR observation of the 105Pd nucleus in inorganic compounds and palladium metal systems.

Hooper TJN, Partridge TA, Rees GJ, Keeble DS, Powell NA, Smith ME, Mikheenko IP, Macaskie LE, Bishop PT, Hanna JV.

Phys Chem Chem Phys. 2018 Nov 7;20(41):26734-26743. doi: 10.1039/c8cp02594k. Epub 2018 Oct 16.

PMID:
30324213
8.

"Of Mice and Measures": A Project to Improve How We Advance Duchenne Muscular Dystrophy Therapies to the Clinic.

Gordish-Dressman H, Willmann R, Dalle Pazze L, Kreibich A, van Putten M, Heydemann A, Bogdanik L, Lutz C, Davies K, Demonbreun AR, Duan D, Elsey D, Fukada SI, Girgenrath M, Patrick Gonzalez J, Grounds MD, Nichols A, Partridge T, Passini M, Sanarica F, Schnell FJ, Wells DJ, Yokota T, Young CS, Zhong Z, Spurney C, Spencer M, De Luca A, Nagaraju K, Aartsma-Rus A.

J Neuromuscul Dis. 2018;5(4):407-417. doi: 10.3233/JND-180324.

9.

A large-scale application of project prioritization to threatened species investment by a government agency.

Brazill-Boast J, Williams M, Rickwood B, Partridge T, Bywater G, Cumbo B, Shannon I, Probert WJM, Ravallion J, Possingham H, Maloney RF.

PLoS One. 2018 Aug 14;13(8):e0201413. doi: 10.1371/journal.pone.0201413. eCollection 2018.

10.

Greater Colo-Rectal Activation Phenotype in Exercised mdx Mice.

Nearing M, Novak J, Partridge T.

PLoS Curr. 2018 May 2;10. pii: ecurrents.md.230ed3d6559b171e10279fc16e9ebef3. doi: 10.1371/currents.md.230ed3d6559b171e10279fc16e9ebef3.

11.

The macrophage as a Trojan horse for antisense oligonucleotide delivery.

Novak JS, Jaiswal JK, Partridge TA.

Expert Opin Ther Targets. 2018 Jun;22(6):463-466. doi: 10.1080/14728222.2018.1482279. Epub 2018 Jun 7. No abstract available.

12.

Discrimination Between Human Leukocyte Antigen Class I-Bound and Co-Purified HIV-Derived Peptides in Immunopeptidomics Workflows.

Partridge T, Nicastri A, Kliszczak AE, Yindom LM, Kessler BM, Ternette N, Borrow P.

Front Immunol. 2018 Apr 27;9:912. doi: 10.3389/fimmu.2018.00912. eCollection 2018.

13.

Author Correction: Myoblasts and macrophages are required for therapeutic morpholino antisense oligonucleotide delivery to dystrophic muscle.

Novak JS, Hogarth MW, Boehler JF, Nearing M, Vila MC, Heredia R, Fiorillo AA, Zhang A, Hathout Y, Hoffman EP, Jaiswal JK, Nagaraju K, Cirak S, Partridge TA.

Nat Commun. 2018 Mar 23;9(1):1256. doi: 10.1038/s41467-018-03709-8.

14.

Ten-Year Trends in Medical Complications Following 540,623 Primary Total Hip Replacements from a National Database.

Partridge T, Jameson S, Baker P, Deehan D, Mason J, Reed MR.

J Bone Joint Surg Am. 2018 Mar 7;100(5):360-367. doi: 10.2106/JBJS.16.01198.

15.

Author Correction: Myoblasts and macrophages are required for therapeutic morpholino antisense oligonucleotide delivery to dystrophic muscle.

Novak JS, Hogarth MW, Boehler JF, Nearing M, Vila MC, Heredia R, Fiorillo AA, Zhang A, Hathout Y, Hoffman EP, Jaiswal JK, Nagaraju K, Cirak S, Partridge TA.

Nat Commun. 2018 Jan 15;9(1):208. doi: 10.1038/s41467-017-02206-8.

16.

Myoblasts and macrophages are required for therapeutic morpholino antisense oligonucleotide delivery to dystrophic muscle.

Novak JS, Hogarth MW, Boehler JF, Nearing M, Vila MC, Heredia R, Fiorillo AA, Zhang A, Hathout Y, Hoffman EP, Jaiswal JK, Nagaraju K, Cirak S, Partridge TA.

Nat Commun. 2017 Oct 16;8(1):941. doi: 10.1038/s41467-017-00924-7. Erratum in: Nat Commun. 2018 Jan 15;9(1):208. Nat Commun. 2018 Mar 23;9(1):1256.

17.

Effects of systemic multiexon skipping with peptide-conjugated morpholinos in the heart of a dog model of Duchenne muscular dystrophy.

Echigoya Y, Nakamura A, Nagata T, Urasawa N, Lim KRQ, Trieu N, Panesar D, Kuraoka M, Moulton HM, Saito T, Aoki Y, Iversen P, Sazani P, Kole R, Maruyama R, Partridge T, Takeda S, Yokota T.

Proc Natl Acad Sci U S A. 2017 Apr 18;114(16):4213-4218. doi: 10.1073/pnas.1613203114. Epub 2017 Apr 3.

18.

ASSOCIATIONS BETWEEN EARLY MATERNAL DEPRESSIVE SYMPTOM TRAJECTORIES AND TODDLERS' FELT SECURITY AT 18 MONTHS: ARE BOYS AND GIRLS AT DIFFERENTIAL RISK?

Beeghly M, Partridge T, Tronick E, Muzik M, Rahimian Mashhadi M, Boeve JL, Irwin JL.

Infant Ment Health J. 2017 Jan;38(1):53-67. doi: 10.1002/imhj.21617. Epub 2017 Jan 2.

19.

Improving patient reported outcome measures (PROMs) in total knee replacement by changing implant and preserving the infrapatella fatpad: a quality improvement project.

Partridge T, Carluke I, Emmerson K, Partington P, Reed M.

BMJ Qual Improv Rep. 2016 May 5;5(1). pii: u204088.w3767. doi: 10.1136/bmjquality.u204088.w3767. eCollection 2016.

20.

Elusive sources of variability of dystrophin rescue by exon skipping.

Vila MC, Klimek MB, Novak JS, Rayavarapu S, Uaesoontrachoon K, Boehler JF, Fiorillo AA, Hogarth MW, Zhang A, Shaughnessy C, Gordish-Dressman H, Burki U, Straub V, Lu QL, Partridge TA, Brown KJ, Hathout Y, van den Anker J, Hoffman EP, Nagaraju K.

Skelet Muscle. 2015 Dec 1;5:44. doi: 10.1186/s13395-015-0070-6. eCollection 2015.

21.

Effect of genetic background on the dystrophic phenotype in mdx mice.

Coley WD, Bogdanik L, Vila MC, Yu Q, Van Der Meulen JH, Rayavarapu S, Novak JS, Nearing M, Quinn JL, Saunders A, Dolan C, Andrews W, Lammert C, Austin A, Partridge TA, Cox GA, Lutz C, Nagaraju K.

Hum Mol Genet. 2016 Jan 1;25(1):130-45. doi: 10.1093/hmg/ddv460. Epub 2015 Nov 12.

22.

Defining the HLA class I-associated viral antigen repertoire from HIV-1-infected human cells.

Ternette N, Yang H, Partridge T, Llano A, Cedeño S, Fischer R, Charles PD, Dudek NL, Mothe B, Crespo M, Fischer WM, Korber BT, Nielsen M, Borrow P, Purcell AW, Brander C, Dorrell L, Kessler BM, Hanke T.

Eur J Immunol. 2016 Jan;46(1):60-9. doi: 10.1002/eji.201545890. Epub 2015 Nov 4.

23.

TNF-α-Induced microRNAs Control Dystrophin Expression in Becker Muscular Dystrophy.

Fiorillo AA, Heier CR, Novak JS, Tully CB, Brown KJ, Uaesoontrachoon K, Vila MC, Ngheim PP, Bello L, Kornegay JN, Angelini C, Partridge TA, Nagaraju K, Hoffman EP.

Cell Rep. 2015 Sep 8;12(10):1678-90. doi: 10.1016/j.celrep.2015.07.066. Epub 2015 Aug 28.

24.

Upregulated IL-1β in dysferlin-deficient muscle attenuates regeneration by blunting the response to pro-inflammatory macrophages.

Cohen TV, Many GM, Fleming BD, Gnocchi VF, Ghimbovschi S, Mosser DM, Hoffman EP, Partridge TA.

Skelet Muscle. 2015 Aug 7;5:24. doi: 10.1186/s13395-015-0048-4. eCollection 2015.

25.

Viruses transfer the antiviral second messenger cGAMP between cells.

Bridgeman A, Maelfait J, Davenne T, Partridge T, Peng Y, Mayer A, Dong T, Kaever V, Borrow P, Rehwinkel J.

Science. 2015 Sep 11;349(6253):1228-32. doi: 10.1126/science.aab3632. Epub 2015 Jul 30.

26.

Muscular dystrophy in the mdx mouse is a severe myopathy compounded by hypotrophy, hypertrophy and hyperplasia.

Duddy W, Duguez S, Johnston H, Cohen TV, Phadke A, Gordish-Dressman H, Nagaraju K, Gnocchi V, Low S, Partridge T.

Skelet Muscle. 2015 May 1;5:16. doi: 10.1186/s13395-015-0041-y. eCollection 2015.

27.

Rhabdomyosarcoma: current challenges and their implications for developing therapies.

Hettmer S, Li Z, Billin AN, Barr FG, Cornelison DD, Ehrlich AR, Guttridge DC, Hayes-Jordan A, Helman LJ, Houghton PJ, Khan J, Langenau DM, Linardic CM, Pal R, Partridge TA, Pavlath GK, Rota R, Schäfer BW, Shipley J, Stillman B, Wexler LH, Wagers AJ, Keller C.

Cold Spring Harb Perspect Med. 2014 Nov 3;4(11):a025650. doi: 10.1101/cshperspect.a025650. Review.

28.

Could exon skipping help dystrophic boys to run, hop, and jump?

Partridge T.

Mol Ther. 2014 Nov;22(11):1884-6. doi: 10.1038/mt.2014.189. No abstract available.

29.

Asynchronous remodeling is a driver of failed regeneration in Duchenne muscular dystrophy.

Dadgar S, Wang Z, Johnston H, Kesari A, Nagaraju K, Chen YW, Hill DA, Partridge TA, Giri M, Freishtat RJ, Nazarian J, Xuan J, Wang Y, Hoffman EP.

J Cell Biol. 2014 Oct 13;207(1):139-58. doi: 10.1083/jcb.201402079.

30.

Discovery of serum protein biomarkers in the mdx mouse model and cross-species comparison to Duchenne muscular dystrophy patients.

Hathout Y, Marathi RL, Rayavarapu S, Zhang A, Brown KJ, Seol H, Gordish-Dressman H, Cirak S, Bello L, Nagaraju K, Partridge T, Hoffman EP, Takeda S, Mah JK, Henricson E, McDonald C.

Hum Mol Genet. 2014 Dec 15;23(24):6458-69. doi: 10.1093/hmg/ddu366. Epub 2014 Jul 15.

31.

Multiple insights from myogenic cell transplants.

Partridge TA, Morgan JE.

Hum Gene Ther. 2014 May;25(5):404-5. doi: 10.1089/hum.2014.035. No abstract available.

PMID:
24848316
32.

Survival motor neuron protein deficiency impairs myotube formation by altering myogenic gene expression and focal adhesion dynamics.

Bricceno KV, Martinez T, Leikina E, Duguez S, Partridge TA, Chernomordik LV, Fischbeck KH, Sumner CJ, Burnett BG.

Hum Mol Genet. 2014 Sep 15;23(18):4745-57. doi: 10.1093/hmg/ddu189. Epub 2014 Apr 23.

33.

Mammals of Australia's tropical savannas: a conceptual model of assemblage structure and regulatory factors in the Kimberley region.

Radford IJ, Dickman CR, Start AN, Palmer C, Carnes K, Everitt C, Fairman R, Graham G, Partridge T, Thomson A.

PLoS One. 2014 Mar 26;9(3):e92341. doi: 10.1371/journal.pone.0092341. eCollection 2014.

34.

What Can We Learn From Clinical Trials of Exon Skipping for DMD?

Lu QL, Cirak S, Partridge T.

Mol Ther Nucleic Acids. 2014 Mar 11;3:e152. doi: 10.1038/mtna.2014.6. No abstract available.

35.

Human skeletal muscle xenograft as a new preclinical model for muscle disorders.

Zhang Y, King OD, Rahimov F, Jones TI, Ward CW, Kerr JP, Liu N, Emerson CP Jr, Kunkel LM, Partridge TA, Wagner KR.

Hum Mol Genet. 2014 Jun 15;23(12):3180-8. doi: 10.1093/hmg/ddu028. Epub 2014 Jan 22.

36.

Anti-tumor activity of the beta-adrenergic receptor antagonist propranolol in neuroblastoma.

Wolter JK, Wolter NE, Blanch A, Partridge T, Cheng L, Morgenstern DA, Podkowa M, Kaplan DR, Irwin MS.

Oncotarget. 2014 Jan 15;5(1):161-72.

37.

Highly efficient in vivo delivery of PMO into regenerating myotubes and rescue in laminin-α2 chain-null congenital muscular dystrophy mice.

Aoki Y, Nagata T, Yokota T, Nakamura A, Wood MJ, Partridge T, Takeda S.

Hum Mol Genet. 2013 Dec 15;22(24):4914-28. doi: 10.1093/hmg/ddt341. Epub 2013 Jul 23.

PMID:
23882132
38.

The mdx mouse model as a surrogate for Duchenne muscular dystrophy.

Partridge TA.

FEBS J. 2013 Sep;280(17):4177-86. doi: 10.1111/febs.12267. Epub 2013 Apr 22. Review.

39.

Defective skeletal muscle growth in lamin A/C-deficient mice is rescued by loss of Lap2α.

Cohen TV, Gnocchi VF, Cohen JE, Phadke A, Liu H, Ellis JA, Foisner R, Stewart CL, Zammit PS, Partridge TA.

Hum Mol Genet. 2013 Jul 15;22(14):2852-69. doi: 10.1093/hmg/ddt135. Epub 2013 Mar 27.

40.

Induction of SerpinB2 and Th1/Th2 modulation by SerpinB2 during lentiviral infections in vivo.

Major LD, Partridge TS, Gardner J, Kent SJ, de Rose R, Suhrbier A, Schroder WA.

PLoS One. 2013;8(2):e57343. doi: 10.1371/journal.pone.0057343. Epub 2013 Feb 27.

41.

Dystrophin deficiency leads to disturbance of LAMP1-vesicle-associated protein secretion.

Duguez S, Duddy W, Johnston H, Lainé J, Le Bihan MC, Brown KJ, Bigot A, Hathout Y, Butler-Browne G, Partridge T.

Cell Mol Life Sci. 2013 Jun;70(12):2159-74. doi: 10.1007/s00018-012-1248-2. Epub 2013 Jan 24.

PMID:
23344255
42.

Oral candidiasis in European hedgehogs.

Barlow A, Partridge T, Clark C, Everest D.

Vet Rec. 2012 Dec 8;171(23):602-3. doi: 10.1136/vr.e8275. No abstract available.

PMID:
23223477
43.

The satellite cell builds its nest under Notch's guidance.

Lepper C, Low S, Partridge TA.

Cell Stem Cell. 2012 Oct 5;11(4):443-4. doi: 10.1016/j.stem.2012.09.010.

44.

Atmospheric oxygen tension slows myoblast proliferation via mitochondrial activation.

Duguez S, Duddy WJ, Gnocchi V, Bowe J, Dadgar S, Partridge TA.

PLoS One. 2012;7(8):e43853. doi: 10.1371/journal.pone.0043853. Epub 2012 Aug 24.

45.

Metabolic remodeling agents show beneficial effects in the dystrophin-deficient mdx mouse model.

Jahnke VE, Van Der Meulen JH, Johnston HK, Ghimbovschi S, Partridge T, Hoffman EP, Nagaraju K.

Skelet Muscle. 2012 Aug 21;2(1):16. doi: 10.1186/2044-5040-2-16.

46.

Extensive and prolonged restoration of dystrophin expression with vivo-morpholino-mediated multiple exon skipping in dystrophic dogs.

Yokota T, Nakamura A, Nagata T, Saito T, Kobayashi M, Aoki Y, Echigoya Y, Partridge T, Hoffman EP, Takeda S.

Nucleic Acid Ther. 2012 Oct;22(5):306-15. doi: 10.1089/nat.2012.0368. Epub 2012 Aug 13.

47.

Bodywide skipping of exons 45-55 in dystrophic mdx52 mice by systemic antisense delivery.

Aoki Y, Yokota T, Nagata T, Nakamura A, Tanihata J, Saito T, Duguez SM, Nagaraju K, Hoffman EP, Partridge T, Takeda S.

Proc Natl Acad Sci U S A. 2012 Aug 21;109(34):13763-8. doi: 10.1073/pnas.1204638109. Epub 2012 Aug 6.

48.

Myogenesis in dysferlin-deficient myoblasts is inhibited by an intrinsic inflammatory response.

Cohen TV, Cohen JE, Partridge TA.

Neuromuscul Disord. 2012 Jul;22(7):648-58. doi: 10.1016/j.nmd.2012.03.002. Epub 2012 May 3.

49.

Effects of placement type on the language developmental trajectories of maltreated children from infancy to early childhood.

Stacks AM, Beeghly M, Partridge T, Dexter C.

Child Maltreat. 2011 Nov;16(4):287-99. doi: 10.1177/1077559511427957. Epub 2011 Dec 5.

PMID:
22146859
50.

Impending therapies for Duchenne muscular dystrophy.

Partridge TA.

Curr Opin Neurol. 2011 Oct;24(5):415-22. doi: 10.1097/WCO.0b013e32834aa3f1. Review.

PMID:
21892079

Supplemental Content

Loading ...
Support Center